Articles tagged with Thrombosis
A large venous thrombosis trial has found that apixaban is safer than rivaroxaban, with 3.3% of participants experiencing clinically relevant bleeding compared to 7.1% with rivaroxaban. This trial has significant implications for clinical practice and patient care.
A study of 2,997 adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and anticoagulants found no increased risks of bleeding or clotting. The findings contradict previous lab results and provide reassurance for clinicians and patients managing anticoagulation alongside modern prostate cancer treatments.
The new guideline provides a clinical classification system to assess the severity of acute pulmonary embolism, which can lower oxygen levels in the blood, damage lung tissue, and put serious strain on the heart. Prompt diagnosis and timely treatment are crucial to prevent severe complications such as cardiac arrest and death.
A new Tulane University study suggests that catheter ablation delivers major benefits for patients diagnosed with both atrial fibrillation and obstructive sleep apnea, significantly lowering the risks of heart failure and death. The study found a 40% drop in major cardiovascular events and a 70% decline in all-cause mortality.
Researchers created a miniaturized replica of carotid arteries using 3D printing, mimicking the geometry and fluid dynamics of human blood vessels. The model revealed that platelet movement is crucial in blood clot formation, and high stress on blood vessels triggers significant platelet activity.
A new study analyzing linked electronic health records found that COVID-19 infections led to a higher and longer-lasting risk of rare heart complications, including myocarditis and thrombocytopenia, compared to vaccination. The research team estimated an additional 2.24 cases of myocarditis per 100,000 children after COVID-19 infection.
Dr. Wei Li's four-year NIH R01 grant investigates the role of sodium/potassium ATPase in regulating platelet activation and thrombosis risk. The study aims to identify new therapeutic targets to reduce blood clot formation and improve patient outcomes.
A recent study by Tarang Parekh reveals that 80% of US adults show signs of CKM syndrome, which increases the risk for cardiovascular disease. The condition progresses in stages, with stage 4 being the most dire, characterized by clinical CVD diagnoses such as heart failure and kidney failure.
Patients with chronic limb-threatening ischaemia (CLTI) are at risk of serious complications, including major amputations and heart attacks. A new statement from the European Society of Cardiology recommends using dual pathway inhibition (DPI) to prevent blood clots in CLTI patients after leg artery procedures.
Researchers at Lund University discovered three gene variants associated with a significantly increased risk of blood clots in the leg. These genetic mutations can lead to a 10-30% higher risk of venous thrombosis and are found in various populations worldwide.
A recent study confirms the benefits of rivaroxaban treatment even after extended use in children, providing reliable evidence for long-term anticoagulation. The research shows a low risk of VTE recurrence and serious bleeding with prolonged treatment, making it a scientifically proven age-appropriate option.
Researchers found that halving vital sign and neurological function checks in low-risk patients after acute ischemic stroke treatment does not compromise care or recovery. The approach also frees up nursing time and intensive care resources, improving hospital capacity.
A new study by Johns Hopkins Medicine researchers identifies anti-TFAM antibodies as a significant risk factor for thrombotic events in people with lupus. These antibodies attack an essential protein crucial for maintaining the health of mitochondria, leading to damage and increased risk of blood clots.
Scientists at UPF and the Royal Veterinary College have generated 3D reconstructions of cat hearts to analyze thrombi formation. The study reveals a similar risk pattern between cats and humans, highlighting the importance of heart morphology in blood clotting.
A new study from Uppsala University investigates how sleep deprivation affects biomarkers associated with cardiovascular disease. Researchers found that chronic lack of sleep increases the risk of heart problems by promoting inflammatory proteins.
Dr. Kenneth Rosenfield is a distinguished interventional cardiologist recognized for his seminal work in endovascular therapy and pioneering innovative techniques. He has made significant contributions to the field of vascular medicine, including the development of self-expanding stents and drug-coated balloons.
A day-long conference brought together experts to present ground-breaking outcomes research on CTEPH treatments. The session covered new medications, refined techniques, and innovative approaches to improve diagnosis and treatment outcomes.
Using intravascular imaging (IVI) to guide stent implantation reduces death, stent thrombosis, and repeat procedures in severely calcified lesions. IVI outperforms conventional angiography in improving patient outcomes.
Stephan Windecker, a world-renowned cardiologist, will be honored with the TCT 2025 Career Achievement Award for his extraordinary contributions to interventional cardiology. His extensive research has shaped clinical practice worldwide and influenced the future of cardiovascular medicine.
Researchers created a thromboinflammation-on-a-chip model that can sustain blood clots for several months and track treatment options. This model reveals critical information on clot resolution and suggests new drug combinations to protect endothelial function in patients with sickle cell disease.
TCT 2025 will take place October 25-28, 2025, at the Moscone Center in San Francisco, California. The event will feature acute interventions, breakthrough technologies, and cutting-edge research driving the next era of cardiovascular care.
A new device has been designed to effectively treat cerebral venous sinus thrombosis (CVST) by navigating complex venous anatomy and removing large thrombi. The device features controllable axial and longitudinal maneuverability, improving clinical outcomes for patients with CVST.
A global study by Amsterdam UMC found that new medication direct oral anticoagulants (DOACs) are equally safe and effective as vitamin K antagonists (VKAs) for treating sinus thrombosis. Regular monitoring is no longer necessary, making it more user-friendly.
A team of researchers has identified a new chronic blood clotting disorder, VITT-like monoclonal gammopathy of thrombotic significance (MGTS), characterized by antibodies similar to those causing vaccine-induced immune thrombocytopenia and thrombosis (VITT). The disorder can lead to severe symptoms despite treatment with full-dose bloo...
A preclinical study reveals that tumors drive clot formation by releasing chemokines, prompting immune cells to release small vesicles that attach to cell fragments, forming life-threatening clots. The findings may lead to diagnostic tests and safer therapies to target the root of blood clotting risk.
A new Northwestern Medicine study reveals that macrophages in newborns use a process called efferocytosis to produce thromboxane, which triggers the production of a bioactive lipid that signals heart muscle cells to divide and regenerate. This process is less effective in adults, leading to scar-tissue buildup and often heart failure.
This study found that combined hormonal contraceptives carry the highest risk of venous thromboembolism, especially those containing third-generation progestins. Intrauterine devices and non-use had no significant difference in risk compared to these products.
The ACC Advancing the Cardiovascular Care of the Oncology Patient conference will provide clinicians with tools to improve cardiovascular care of cancer patients. Key sessions will include discussions on pulmonary tumor thrombotic microangiopathy, AI and technology in cardio-oncology.
A predictive model developed by Ochsner Health researchers uses data-driven insights to determine whether urgent carotid-intervention patients will regain functional independence. The model has been shown to have a 93% accuracy rate and can help physicians tailor treatment plans and optimize intervention timing.
A recent study by Michigan Medicine found that reducing the dose of popular blood thinners like Xarelto and Eliquis can lower the risk of future bleeding events. The research team analyzed nearly 1,000 cases of patients who took these medications to prevent recurrent clots after having a blood clot.
A large US study found a strong association between long-term air pollution exposure and an increased risk of blood clots in deep veins, also known as venous thromboembolism. Participants with higher exposure to particulate matter, oxides of nitrogen, and nitrogen dioxide had a significantly increased risk of developing these conditions.
Researchers analyzed the effects of seven hormone treatments on blood clots, stroke, and heart attack in nearly one million women. The study shows that the risks differ depending on the type of treatment, with some linked to increased cardiovascular disease risk and others to no increased risk.
Researchers discover how post-translational modifications alter fibrinogen structure and function, impacting thrombotic disorders and developing advanced treatment strategies. The study identifies potential molecular targets for drug development and emphasizes the need for further exploration of less-characterized PTMs.
Research published in European Heart Journal reveals that taking an NSAID with anticoagulant medication increases the risk of internal bleeding. The study found a significant increase in bleeding risks for various organs, including gut, brain, lungs, and bladder.
A Korean University College of Medicine study investigated COVID-19 vaccine safety in patients with atrial fibrillation/flutter. The research found no significant increase in the risk of thromboembolic events following COVID-19 vaccination, but patients without anticoagulant therapy were at higher risk. The study highlights the importa...
Researchers have developed a practical calculator to predict the risk of developing epilepsy after cerebral venous thrombosis, a rare cause of stroke. The tool is based on factors already available in clinical routine and can help inform treatment decisions or support preventive medication for those at high risk.
Researchers found that imbalances in neutrophil extracellular traps are associated with portal vein thrombosis in patients with decompensated cirrhosis. High histone-DNA levels and low DNase activity were identified as independent risk factors for PVT.
Researchers from Brazil's Center for Research on Redox Processes in Biomedicine found that high blood sugar can cause thrombosis by altering endothelial function and promoting platelet adhesion. They identified a specific molecular mechanism involving protein disulfide isomerase A1 as a key regulator of this process.
The Cardiovascular Research Foundation recognizes 29 leading institutions for their contributions to groundbreaking research advancing interventional cardiovascular medicine. The 2024 SET-10 rankings celebrate institutions making significant impacts across various categories, including basic science and clinical research.
Research suggests standing for long periods does not improve cardiovascular health and may increase circulatory issues. Sitting for over 10 hours a day was found to increase cardiovascular disease risk, highlighting the need for regular movement throughout the day.
A Brazilian study found that high blood pressure hardens the bronchi and increases airway resistance, reducing respiratory capacity. Regular physical activity may partially protect against this hardening.
A new study found that nursing shortages result in longer hospital stays and worse patient outcomes, including higher mortality rates. Understaffing by registered nurses and nurse assistants is associated with increased risks of adverse events, such as readmissions, deep vein thrombosis, pneumonia, and pressure ulcers.
Endomimetics is developing a Bionanomatrix coating to accelerate aneurysm occlusion and minimize thrombus formation in brain aneurysm patients. The coating promotes endothelialization through five synergistic elements, reducing inflammatory responses and platelet adhesion.
Researchers found that adopting an electronic patient management system for direct oral anticoagulants reduced off-label dosing by 8%, while also decreasing the rate of blood clots and strokes. The online dashboard, used at over 120 hospitals, highlights treatment optimization and improves patient safety.
Research analyzing 4.184 million genetic data from 23andMe participants found that those with sickle cell trait have a higher risk of venous thromboembolism and pulmonary embolism, yet relatively lower risk of blood clotting overall compared to FVL.
A clinical trial led by Washington University School of Medicine found that two anti-coagulant drugs did not improve outcomes for patients who received vessel-clearing interventions after a blood clot in the brain. The study aimed to test whether adding these medications could prevent further clots, but results showed no benefit.
A randomized trial found that continuing oral anticoagulants after transcatheter aortic valve implantation did not reduce thromboembolic events but increased bleeding risk. The study suggests interrupting OACs may be beneficial for patients undergoing TAVI.
A new textured heart valve implant has been shown to be less likely to cause clotting, improving health outcomes for patients who receive the implant. Certain conditions such as cancer and smoking elevate the risk of blood clots after heart surgery.
A new study by the Cleveland Clinic found that consuming foods with erythritol increases the risk of cardiovascular events such as heart attack and stroke. The artificial sweetener makes platelets more active, which can raise blood clot risks. This research adds to evidence that erythritol may not be as safe as previously thought.
A study by Michigan Medicine found that over- or under-dosing anticoagulants can result in serious health conditions, most often occurring after the initial prescription. The researchers evaluated five years of prescribing data and found that nearly 70% of alerts to off-label dosing occurred during a follow-up visit.
Researchers found that anxiety disorders and depression significantly elevate the risk of incident DVT. Stress-related neural mechanisms may increase DVT risk through heightened activation of stress pathways.
Researchers investigated the effectiveness of systemic thrombolysis for acute portal vein thrombosis (PVT) in liver cirrhosis patients. After a 7-day treatment period, 60% of patients achieved full recanalization of the portal vein, with no significant side effects.
A study investigated current outcomes after revascularization for angiographically confirmed very late stent thrombosis (VLST), revealing a total MACE rate of 35.46%. Left ventricular ejection fraction and peak troponin I at VLST onset were independent predictors of MACE.
A new anticoagulant with on-demand reversible activity has been developed by a team from UNIGE and the University of Sydney. This breakthrough offers a more reliable and easier-to-use option for surgical procedures, reducing the risk of serious bleeding associated with current treatments.
Researchers at Rensselaer Polytechnic Institute have developed a patented process to produce heparin in the lab, offering a consistent and safe supply of the essential medicine. The discovery has the potential to revolutionize the production of heparin, reducing reliance on animal-derived sources and addressing global supply chain issues.
A study found that 2-methylbutyrylcarnitine (2MBC), a gut microbial metabolite, exacerbates thrombosis and is accumulated in COVID-19 patients. Elevated 2MBC levels are associated with increased blood clot risk, suggesting a potential mechanism linking gut microbiota dysbiosis to cardiovascular disease.
Using intravascular imaging to guide stent implantation significantly improves survival and reduces adverse cardiovascular events compared to angiography-guided PCI. The study found a 25% reduction in all-cause death, 45% reduction in cardiac death, and improved outcomes for patients with coronary artery disease.
A randomized clinical trial of 1,680 patients with acute ischemic stroke due to large-vessel occlusion found no significant improvement in disability with adjunctive methylprednisolone. The study suggests that methylprednisolone may not be effective as an adjunct therapy after endovascular thrombectomy for this patient population.
A study of 352 patients found that endovascular thrombectomy benefits both directly presenting and transferred patients with large ischemic strokes, with better functional outcomes observed in those presenting directly to EVT-capable centers. Prolonged transfers worsened outcomes due to evolving ischemic change.
Researchers found that adding blood thinners to clot-busting medications for ischemic strokes did not improve physical function at 90 days post-stroke. The study, MOST, enrolled 514 patients and analyzed the effectiveness of two blood-thinning medications.